Physician-Modified Fenestrated and Branched Aortic Endografting for TAAA

Last updated: September 22, 2025
Sponsor: Yale University
Overall Status: Active - Not Recruiting

Phase

N/A

Condition

Aneurysm

Cardiovascular Disease

Heart Disease

Treatment

Physician-modified aortic endograft

Clinical Study ID

NCT02989948
D18194
2000035699
  • Ages 50-95
  • All Genders

Study Summary

The primary clinical objective of this study is to evaluate the safety and effectiveness of a physician-modified, fenestrated and branched aortic endoprosthesis for the treatment of thoracoabdominal aortic aneurysms (TAAAs). The goal of the primary analysis is to demonstrate both the safety and effectiveness of using a physician-modified fenestrated Cook Zenith Alpha Thoracic Endovascular Graft as compared to previously published results of open surgical replacement of the aneurysmal aorta.

Eligibility Criteria

Inclusion

MAIN ARM - Inclusion Criteria:

  1. Must be a man or woman 50 years of age or older by the date of informed consent.

  2. Must have a thoracoabdominal aortic aneurysm of any Crawford classification (extentI-V) that extends no more proximal than the left subclavian artery.

  3. Must have an aneurysm size that meets standard indications for surgical repair (6.0cm in maximum diameter in the descending thoracic aorta, or 5.5 cm in maximumdiameter in the abdominal aorta).

  4. Must be considered, in the judgment of the S-I, to be a high risk candidate for opensurgical repair.

  5. Must not be a candidate for repair under the Instructions for Use of a commerciallyavailable, FDA-approved endovascular graft.

  6. Must be able to provide informed consent.

  7. Must be able to comply with the five year study assessment schedule of events.

  8. Must have a non-aneurysm-related life expectancy, in the judgment of the S-I, ofgreater than 2 years.

Exclusion

MAIN ARM - Exclusion Criteria:

  1. Aneurysm due to acute or chronic dissection, intramural hematoma, penetrating aorticulceration, pseudoaneurysm, mycotic aneurysm, or traumatic transection.

  2. Ruptured or acutely symptomatic aortic aneurysm.

  3. Known connective tissue disorder.

  4. Imaging demonstrating any of the following:

  • Lack of 20 mm non-aneurysmal proximal seal zone (zone 3, or zone 2 with acarotid-subclavian bypass or transposition).

  • Lack of 15 mm non-aneurysmal distal seal zone(s) (aortic, common iliac, orexternal iliac).

  • Branch vessel target (renal, superior mesenteric, or celiac) < 5 mm or > 10 mmin average diameter.

  • Untreated left subclavian artery stenosis or occlusion.

  • Untreated unilateral or bilateral hypogastric artery occlusion.

  • Signs that the inferior mesenteric artery is indispensable.

  • Have branching, duplication, aneurysm, or untreatable stenosis of the celiac,superior mesenteric artery, or renal arteries that would preclude implantationof the investigational devices.

  1. Known sensitivities or allergies to stainless steel, PTFE, polyester, polypropylene,nitinol, or gold.

  2. History of anaphylaxis to contrast, with inability to prophylax appropriately.

  3. Have uncorrectable coagulopathy.

  4. Have unstable angina.

  5. Have a body habitus that would inhibit X-ray visualization of the aorta.

  6. Have a major surgical or interventional procedure unrelated to the treatment of theaneurysm planned ≤30 days of the endovascular repair.

  7. Known to be participating in any other clinical study which may affect performanceof this device.

  8. Known, visible, or suspected pregnancy, confirmed with a Urine Pregnancy Test (UPT)

  9. Contraindication to oral antiplatelet therapy.

  10. Prisoners or those on alternative sentencing.

  11. Known systemic infection with potential for endovascular graft infection.

  12. Anticipated need for MRI scanning within 3 months of insertion of investigationalproduct.

  13. Other conditions or comorbidities that, in the opinion of the S-I, would exclude thepatient.

EXPANDED ACCESS ARM - Inclusion Criteria

  1. Must be a man or woman 50 years of age or older by the date of informed consent

  2. Must have a thoracic, thoracoabdominal, or abdominal aortic aneurysm thatnecessitates coverage of one or more visceral vessels (celiac, superior mesenteric,or renals) for establishment of proximal and/or distal seal.

  3. Must have an aneurysm size that meets standard size indications for surgical repair (6.0 cm in maximum diameter in the descending thoracic aorta, or 5.5 cm in maximumdiameter in the abdominal aorta); or, in the judgment of the S-I, has aneurysmcharacteristics that portend a high risk of near-term rupture

  4. Must be considered, in the judgement of the S-I, to be a high risk candidate foropen surgical repair

  5. Must not be a candidate for repair under the Instructions for Use of a commerciallyavailable, FDA-approved endovascular graft

  6. Patient must be able to provide informed consent

  7. Must be able to comply with the five year study assessment schedule of events

  8. Must have a non-aneurysm-related life expectancy, in the judgement of the S-I, ofgreater than 2 years

EXPANDED ACCESS ARM - Exclusion Criteria

  1. Known or suspected mycotic aneurysm

  2. Ruptured aneurysm with hemodynamic instability

  3. Known connective tissue disorder

  4. Imaging demonstrating any of the following:

  • Lack of 20 mm non-aneurysmal proximal seal zone (in either native aorta,elephant trunk graft, or aortic arch endograft)

  • Lack of 15 mm non-aneurysmal distal seal zone(s) (in either native aortoiliacvessels, prosthetic aortoiliac grafts, or aortoiliac endografts)

  • Branch vessel target (renal, superior mesenteric, or celiac) > 10 mm in averagediameter

  1. Known sensitivities or allergies to stainless steel, PTFE, polyester, polypropylene,nitinol, or gold

  2. History of anaphylaxis to contrast, with inability to prophylax appropriately.

  3. Have uncorrectable coagulopathy

  4. Have a body habitus that would inhibit X-ray visualization of the aorta

  5. Have a major surgical or interventional procedure unrelated to the treatment of theaneurysm planned ≤ 30 days of the endovascular repair

  6. Known to be participating in any other clinical study which may affect performanceof this device

  7. Known, visible, or suspected pregnancy, confirmed with a Urine Pregnancy Test (UPT)

  8. Contraindication to oral antiplatelet therapy

  9. Prisoners or those on alternative sentencing

  10. Known systemic infection with potential for endovascular graft infection

  11. Anticipated need for MRI scanning within 3 months of insertion of investigationalproduct

  12. Other conditions or comorbidities that, in the opinion of the S-I, would exclude thepatient

Study Design

Total Participants: 38
Treatment Group(s): 1
Primary Treatment: Physician-modified aortic endograft
Phase:
Study Start date:
April 22, 2020
Estimated Completion Date:
December 31, 2031

Study Description

This study is a prospective, two-arm, traditional feasibility study of a physician modified fenestrated Cook Zenith Alpha Thoracic Endovascular Graft base device in adult patients meeting traditional size criteria for open surgical treatment of thoracoabdominal aortic aneurysms (TAAAs). Patients meriting surgical treatment of their aneurysm that also meet inclusion and exclusion criteria will be eligible for enrollment. Patients will be followed for 5 years post procedure. Major adverse events (MAEs) will also be recorded by the Sponsor-Investigator (S-I) and will be monitored by a locally appointed Data Monitoring Committee, Dartmouth-Hitchcock Health and the D-HH Human Research Protection Program IRB/IEC, and the FDA. This record was transferred to Yale in October 2024.

Connect with a study center

  • Tracey MacDermott

    Aurora, Colorado 80220
    United States

    Site Not Available

  • Yale New Haven Hospital

    New Haven 4839366, Connecticut 4831725 06510
    United States

    Site Not Available

  • Dartmouth-Hitchcock Medical Center

    Lebanon, New Hampshire 03756
    United States

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.